FY2026 EPS Estimates for Enanta Pharmaceuticals, Inc. Reduced by Analyst (NASDAQ:ENTA)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTAGet Rating) – Equities research analysts at Jefferies Financial Group reduced their FY2026 EPS estimates for Enanta Pharmaceuticals in a research note issued to investors on Monday, November 21st. Jefferies Financial Group analyst A. Tewari now forecasts that the biotechnology company will post earnings of $2.05 per share for the year, down from their prior estimate of $2.36. The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($2.99) per share.

Enanta Pharmaceuticals (NASDAQ:ENTAGet Rating) last posted its quarterly earnings results on Monday, November 21st. The biotechnology company reported ($1.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.10. The firm had revenue of $20.32 million for the quarter, compared to analyst estimates of $22.86 million. Enanta Pharmaceuticals had a negative net margin of 141.31% and a negative return on equity of 34.73%. Enanta Pharmaceuticals’s quarterly revenue was down 13.8% on a year-over-year basis. During the same period in the previous year, the business posted ($1.22) earnings per share.

ENTA has been the topic of several other reports. JMP Securities reiterated a “buy” rating and issued a $96.00 target price on shares of Enanta Pharmaceuticals in a report on Tuesday. Royal Bank of Canada decreased their target price on shares of Enanta Pharmaceuticals from $65.00 to $54.00 and set a “sector perform” rating on the stock in a report on Tuesday. Oppenheimer set a $50.00 target price on shares of Enanta Pharmaceuticals in a report on Thursday. StockNews.com initiated coverage on shares of Enanta Pharmaceuticals in a report on Wednesday, October 12th. They issued a “hold” rating on the stock. Finally, SVB Leerink boosted their target price on shares of Enanta Pharmaceuticals from $44.00 to $50.00 and gave the company a “market perform” rating in a report on Monday, August 1st. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $67.43.

Enanta Pharmaceuticals Price Performance

NASDAQ:ENTA opened at $45.00 on Wednesday. The firm has a market capitalization of $932.85 million, a price-to-earnings ratio of -7.61 and a beta of 0.53. The company’s 50-day moving average is $47.82 and its two-hundred day moving average is $51.17. Enanta Pharmaceuticals has a 1-year low of $37.59 and a 1-year high of $92.90.

Institutional Investors Weigh In On Enanta Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Signaturefd LLC increased its stake in Enanta Pharmaceuticals by 86.7% during the 1st quarter. Signaturefd LLC now owns 392 shares of the biotechnology company’s stock worth $28,000 after buying an additional 182 shares during the period. Nisa Investment Advisors LLC increased its stake in Enanta Pharmaceuticals by 164.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,207 shares of the biotechnology company’s stock worth $57,000 after buying an additional 750 shares during the period. Captrust Financial Advisors increased its stake in Enanta Pharmaceuticals by 343.8% during the 1st quarter. Captrust Financial Advisors now owns 852 shares of the biotechnology company’s stock worth $61,000 after buying an additional 660 shares during the period. Point72 Hong Kong Ltd increased its stake in Enanta Pharmaceuticals by 83.7% during the 2nd quarter. Point72 Hong Kong Ltd now owns 1,565 shares of the biotechnology company’s stock worth $74,000 after buying an additional 713 shares during the period. Finally, Quantbot Technologies LP increased its stake in Enanta Pharmaceuticals by 13,411.8% during the 2nd quarter. Quantbot Technologies LP now owns 2,297 shares of the biotechnology company’s stock worth $108,000 after buying an additional 2,280 shares during the period. 97.09% of the stock is owned by hedge funds and other institutional investors.

About Enanta Pharmaceuticals

(Get Rating)

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.

Featured Articles

Earnings History and Estimates for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.